India’s Pharma Exports to Brazil Rise 17% YoY; Healthcare Meet Signals Next Growth Phase

Shipments cross $778 million; focus shifts to biosimilars, complex therapies and MSME-led specialty medicines

New Delhi: India’s pharmaceutical exports to Brazil recorded a 17% year-on-year growth, crossing $778 million in FY 2024-25, as industry leaders from both countries met in New Delhi to deepen bilateral healthcare cooperation.

The Pharmaceutical Export Promotion Council of India (Pharmexcil) supported the India–Brazil Healthcare Business Gateway held at Taj Palace, which brought together Indian pharma manufacturers, Brazilian healthcare leaders and representatives of ANVISA, Brazil’s health regulatory authority. The discussions focused on oncology medicines, biosimilars, complex therapies and hospital technologies, alongside regulatory compliance pathways for faster market entry.

According to the export data shared during the meeting, total pharmaceutical exports to Brazil reached $778.49 million in FY 2024-25, marking an 18.74% increase from $655.64 million in FY 2023-24. During April–January FY26, exports stood at $740.33 million, reflecting a 17.03% growth over the same period in FY25. Brazil currently accounts for approximately 2.88% of India’s total pharmaceutical exports and ranks as the second-largest destination by share.

Formulations Drive Growth

As shown in the export performance table (page 1), drugs formulations and biologicals emerged as the primary growth driver, registering 35.96% growth and contributing 61.10% of total exports during April 2025–January 2026. Bulk drugs and drug intermediates grew 15.26%, accounting for 29.28% share. Vaccines, surgicals, and Ayush & herbals recorded negative growth during the period.

Pharmexcil chairman Namit Joshi said Brazil presents a significant opportunity for Indian MSME pharmaceutical manufacturers, particularly in specialty medicines, public healthcare supply and technology partnerships. He noted that Indian firms have both the technological capability and manufacturing scale to expand access to high-quality medicines in Brazil.

Guilherme Lima, CEO of Amoveri Farma, said the meeting represents a key step toward expanding pharmaceutical collaboration and improving access to advanced treatments in Brazil through partnerships with Indian manufacturers.

Regulatory and Market Access Focus

The meeting included participation from Amoveri Farma leadership, ANVISA representatives and regulatory specialists, underscoring the importance of regulatory alignment and structured access to the Brazilian market. Discussions also covered compliance requirements and responsible market entry mechanisms.

Pharmexcil said it will continue strengthening global engagement platforms, including iPHEX 2026 scheduled for September 7–9, 2026, aimed at showcasing India’s pharmaceutical capabilities and fostering international partnerships.

With over 4,679 members, Pharmexcil functions as the apex export promotion council for the Indian pharmaceutical industry under the ministry of commerce and industry, supporting exporters and advancing bilateral market access initiatives.